What are the most valuable healthcare AI agent startups?

Top startups in the healthcare AI agents market ranked by valuation

Here is the current ranking of the most valuable healthcare AI agents startups. For each one you will also find our confidence level and the valuation basis we used.

If you want to go deeper into the healthcare AI agents startup landscape, check our report covering the healthcare AI agents market.

1. Total funding: equity-only minimum; excludes disclosed venture debt.

Is Abridge still the most valuable healthcare AI agent startup?

Yes, Abridge remains the most valuable healthcare AI agent startup at $5.3B, backed by substantial hospital deployments.

The valuation came with Abridge's major June 2025 financing. The product began by drafting notes from clinical conversations, then expanded into structured records, coding, and tasks linked to reimbursement. That gives hospitals a reason to consider the product beyond time saved during a visit.

Abridge described relationships with more than 150 enterprise health systems in June 2025. In August 2026, it said more than 300 health systems had adopted its newer context-aware decision-support product. These are different measures, so we do not treat them as a like-for-like growth rate. But the newer rollout shows that Abridge is getting healthcare organizations to try tools beyond basic note-taking.

Could Hippocratic AI overtake Abridge in healthcare AI?

Hippocratic AI could overtake Abridge one day, but its announced $3.5B valuation still trails the healthcare AI agent leader.

Hippocratic AI raised a $126M Series C in November 2025 for patient-facing agents that handle outreach, chronic-care programs, and follow-up. Its business depends on doing many calls safely and knowing when a person must take over.

WellSpan Health said in July 2026 that the Ana agent was handling more than 160,000 patient calls a month. Hippocratic AI introduced technology for coordinating specialist agents in August 2026. If the business grows from individual calls into lasting care programs, its potential market expands. For now, the stated valuation gap remains real.

Is Forus really worth billions as a healthcare AI company?

Yes, Forus has an announced $3.0B valuation for its healthcare AI medication-access network.

Forus raised a $150M Series C in September 2026, led by Bain Capital Ventures. Its agents coordinate the paperwork and actions between a prescription and a patient receiving medicine, including coverage checks, authorizations, pharmacy work, and financial assistance.

The company's May 2026 launch described the delays caused when physicians, insurers, pharmacies, and manufacturers use separate systems. Forus is trying to make that journey work as one connected process. The value depends on whether it can keep completing those tasks reliably at scale, but the announced price shows how highly investors rate the problem.

Why is Ambience Healthcare worth more than $1B?

Ambience Healthcare is valued at $1.3B because its clinical AI platform covers documentation, coding, and record review.

Its $243M Series C in July 2025 funded a product that turns a conversation into more than a physician's note. Coding and documentation accuracy affect what a hospital can bill, so the software sits inside an important financial process as well as a clinical one.

Cleveland Clinic announced a rollout in February 2025, and a November 2026 KLAS Research study described results from Memorial Hermann. Those deployments make the platform easier to evaluate than an unreleased product. The remaining test is whether hospitals continue paying as competing documentation and coding tools improve.

Is Assort Health really a healthcare AI unicorn?

Yes, Assort Health is reportedly valued at $1.2B, with its business built around patient scheduling and access agents.

The reported price accompanied a $120M Series C in June 2026. Assort's agents schedule visits, handle intake and referrals, and respond to patient requests. Providers can measure how many calls are resolved and how many appointments get booked, which makes the product easier to judge than a general conversational assistant.

Assort Health announced senior sales and customer-success hires in July 2026 to support larger installations. The company has to connect with actual calendars, records, and clinic rules. The valuation remains a reported figure, not one the company publicly announced, but the work it automates is concrete.

How many healthcare AI agent startups are really unicorns?

We count 5 healthcare AI agent startups with valuations firmly above $1B: Abridge, Hippocratic AI, Forus, Ambience Healthcare, and Assort Health.

Abridge, Hippocratic AI, Forus, and Ambience Healthcare have announced valuations. Assort Health's valuation was reported by the press. We leave out companies whose ranges merely cross the threshold, because the lower end still sits below it.

That distinction is particularly important in private markets. A financing can reveal an agreed price or disclose little beyond the cash invested. Only the first tells us what investors actually paid. Without a published stake or share price, we do not turn the cash raised into a price.

The table below shows selected healthcare AI agent companies with announced or reported prices, alongside a few clearly sub-unicorn comparisons.

Startup	Valuation
Abridge	$5.3B
Hippocratic AI	$3.5B
Forus	$3.0B
Ambience Healthcare	$1.3B
Assort Health	$1.2B
Heidi Health	$900M
Tennr	$605M
Arbiter	$400M

Is Candid Health already a billion-dollar healthcare AI startup?

Candid Health is not a confirmed healthcare AI unicorn: we estimate its valuation at $800M–$1.5B from the size of its last round.

The company raised a $120M Series D+ in July 2026 to expand automated medical billing. Its system handles claims and other revenue-cycle tasks, and providers can judge the value by fewer errors, faster reimbursement, and less manual correction.

The range is our estimate from the size of the July 2026 round, not a price announced by the company or the stake investors bought. Candid may eventually clear the threshold, but treating the high end as a completed transaction would overstate what is known today. We rank a range on its proportional midpoint, which is why Candid sits seventh, behind Luma Health and ahead of Heidi Health's announced price, even though its lower end is below $1B.

Could Tandem Health become Europe's first healthcare AI unicorn?

Tandem Health could reach unicorn status, but its $667M–$1.2B valuation is still an estimate, not a confirmed price.

We estimated that range from the size of Tandem Health's $100M Series B in September 2026 and date it to that financing. The Swedish startup is expanding from clinical documentation into broader clinic operations across European markets.

Australia's Heidi Health has an announced $900M valuation. Tandem ranks above Heidi because we order ranges by their proportional midpoint, but its range overlaps that price, so we cannot say with confidence that Tandem is worth more. Its opportunity lies in working across different languages, health systems, and local requirements, all of which make large-scale software deployment demanding.

Is Notable still worth close to $1B in healthcare AI?

Notable may be worth close to $1B, but its $667M–$1.2B healthcare AI valuation is based on an older estimated price.

We estimated that range from the size of Notable's $100M Series B in November 2021 and date it to that round. The company was automating patient and clinician administration before today's generative AI boom. Its age gives it a long product history, but its last known fundraising terms tell us much less about what investors would pay now. The round is also close to the five-year limit after which we no longer draw an estimate from it.

Tennr was reportedly valued at $605M in June 2025, a more recent observed price for a referral automation business. Notable's modeled range ranks above Tennr, and even above Heidi Health's announced price, because we order ranges by their proportional midpoint, but it should carry less weight than a current reported transaction. The difference is especially important when readers compare two private startups.

Is Suki's healthcare AI business worth $1B yet?

Suki is not yet a confirmed healthcare AI unicorn. We estimate its valuation at $600M–$1.1B.

That estimate comes from the size of Suki's $90M Series D+ in October 2026 and is dated to that round, rather than an announced company price. Suki has raised $255M in equity and now offers tools for documentation, clinical reasoning, and reimbursement workflows.

Suki also sells through healthcare software partners that embed its technology. That could give it a much larger customer base, but an estimated upper bound is not proof that investors have priced the company above $1B. More information on revenue and repeat use would make the valuation easier to judge.

Are billion-dollar valuations becoming common in healthcare AI agents?

No, billion-dollar prices remain rare among healthcare AI agent startups, despite the attention paid to the leaders.

We track 194 startups in this valuation comparison. Of those, 187 sit in the below-$1B valuation bracket, or 96% by company count. The rest are the 5 confirmed unicorns plus Luma Health and Candid Health, whose estimated ranges have a midpoint above $1B even though their lower ends are below it. Many businesses have not disclosed a recent price, and some ranges reach above the unicorn line only at the upper end.

We find 12 valuations stated by a source. The other 182 require estimates. Those figures help explain why a big round is not automatically evidence of a billion-dollar company. Investors have priced a few healthcare agents very highly, but the market as a whole is much less mature.

Could autonomous medical billing create another healthcare AI unicorn?

Yes, autonomous billing could produce another healthcare AI unicorn, but the leading companies have not all reached confirmed billion-dollar prices.

Candid Health's estimated range crosses that line. AKASA is valued at an estimated $450M–$950M from comparable companies and CodaMetrix at $250M–$480M on the same method, while Fathom is estimated at $309M–$579M from the size of an earlier priced round. These are modeled prices, not amounts a buyer has publicly agreed to pay.

The software checks clinical records against payer requirements, creates claims, and fixes problems that delay payment. Charta Health's November 2026 financing highlighted chart review before billing, while Candid works across more of the revenue cycle. We would judge the strongest businesses by how reliably they get claims paid, not simply by the size of the healthcare billing market.

Could healthcare AI startups that handle insurance approvals become unicorns?

Healthcare AI agents for insurance approvals could reach unicorn valuations, but none of the leaders has a published price.

We estimate Cohere Health at $600M–$1.1B from the size of its $90M Series C in May 2025, and Latent Health at $400M–$667M from its $80M Series A in March 2026. For Alaffia Health, we estimate $367M–$688M from the size of its February 2026 last round, dated to that financing. None of the three companies announced a price.

Cohere helps insurers and providers make authorization decisions, Latent coordinates evidence for medication access, and Alaffia checks claims. All have to follow medical records, payer rules, and human review. A higher price will be easier to defend when customers can measure faster approvals without more mistakes.

Can a new healthcare AI agent startup be worth hundreds of millions?

Yes, Arbiter announced a $400M valuation at its $52M Seed round in November 2025, before it had a long deployment history.

Arbiter pitched a platform for coordinating referrals, follow-up, and information exchange between providers, payers, and patients. Investors were paying for an ambitious product and the team's ability to build it, long before there was a mature record of recurring revenue.

That early price sets a difficult test. Arbiter must prove its system can complete real tasks safely and win paying customers over time. A broad vision can attract investors, but hospitals will judge whether it works in their daily processes.

Are European healthcare AI startups catching up on valuation?

European healthcare AI agent startups are gaining ground, but their valuations remain below the highest stated American prices.

Sweden's Tandem Health has an estimated $667M–$1.2B range from its September 2026 last round, based on the round's size and dated to that month. Denmark's Corti is estimated at $400M–$750M from the size of its September 2023 last round. France's Nabla is estimated at $350M–$750M from comparable companies, because an older $180M price was followed by a round without a published price. Germany's Voize is estimated at $250M–$417M from its last round.

Tandem sells clinical assistance that can extend into clinic operations, Corti provides clinical AI infrastructure, Voize works on nursing documentation, and Nabla builds clinical workflow tools. Each needs to fit local systems and languages. There are credible regional companies, but we have no basis to call any one of them an announced European healthcare AI unicorn.

Are the most valuable healthcare AI agent startups mostly American?

Yes, American startups hold the highest announced healthcare AI agent valuations and account for 149 of the 194 businesses we compare.

Abridge, Hippocratic AI, Forus, Ambience Healthcare, and Assort Health are all based in the United States. Their products address documentation, patient calls, medication access, and insurance administration in a healthcare system where coordinating those steps is costly.

There are serious companies elsewhere, including Australia's Heidi Health, Sweden's Tandem Health, and Brazil's Rivio. The country totals count startups only, not their combined value or the amount investors have contributed. They show where these businesses are based, while the company valuations show who leads on price.

The table below shows the largest country groups in our healthcare AI agent valuation comparison.

Country	Startups
United States	149
United Kingdom	6
France	6
Australia	4
Brazil	4
Belgium	3
Germany	3
Israel	3

Does raising more money make a healthcare AI startup worth more?

No, the amount a healthcare AI agent startup has raised does not determine what investors think it is worth.

Ambience Healthcare has raised at least $313M, while Forus has raised at least $275M. Even so, Forus's announced $3.0B valuation is more than twice Ambience's $1.3B.

Heidi Health has raised $191M and has an announced $900M valuation. Tennr has raised $156M and is reportedly valued at $605M. Buyers, revenue, customer adoption, and growth prospects matter in a valuation. Past funding mainly tells us how much outside equity the company has used to get there.

Are healthcare AI startups worth far more than they have raised?

Yes, some healthcare AI agent valuations are many times the equity raised, but the gaps differ sharply by company.

Brazil's Rivio has the highest valuation-to-funding multiple in our comparable group at 11.9x, while Tennr sits at 3.9x. Hippocratic AI records 8.7x and Arbiter 7.7x. We only use values stated by a source, alongside complete funding totals.

These ratios compare company valuation with dollars raised, not annual revenue. A high number may reflect investor expectations for growth after a small amount of equity. A lower one can reflect years of rounds. Rivio checks hospital bills in Brazil while Tennr handles specialist referrals in the US, so a larger multiple alone says little about who has the stronger business.

The table below shows the valuation-to-funding multiples we can compute from stated company values and complete equity totals.

Startup	Multiple
Rivio	11.9x
Hippocratic AI	8.7x
Arbiter	7.7x
Assort Health	5.4x
Heidi Health	4.7x
Qventus	4.1x
Tennr	3.9x

Could patient-access AI become worth more than medical scribes?

Yes, patient-access healthcare AI agents already have some of the market's highest valuations and could eventually overtake documentation specialists.

Hippocratic AI runs patient-facing conversations, Forus coordinates medication access, and Assort Health handles appointments and intake. Their products solve different problems from Abridge and Ambience Healthcare, which begin with clinicians' notes and then take on related work.

Artera.io has a $433M–$812M low-confidence valuation estimate from the size of its December 2025 last round, dated to that financing. Luma Health is estimated at $867M–$1.6B from the size of its $130M Series C in November 2021, which puts it sixth. That round is five years old, so the range says what investors paid then more than what the company is worth today. These older access platforms may have a distribution advantage because they already work with provider organizations. The biggest question is how much more care coordination they can automate without losing reliability.

So, which healthcare AI agent startups are worth the most today?

Abridge is the most valuable healthcare AI agent startup today, with Hippocratic AI and Forus the strongest confirmed challengers.

The leading companies now span clinical documentation, patient communication, medication access, and revenue-cycle work. Ambience Healthcare and Assort Health complete the confirmed unicorn group. Luma Health, Candid Health, Tandem Health, and other promising businesses have valuation ranges that require more care, especially when their figures come from the size of a last round.

The table below shows what we found.

Question	Answer
Who currently sets the highest private price?	Abridge leads the healthcare AI agent market on observed valuation. Its lead over Hippocratic AI stands at 1.5x. Broad hospital integration supports the investor case for its platform.
Can patient communication challenge the documentation leader?	It can, and voice-agent companies have established valuable businesses. Hippocratic AI raised a $126M Series C in November 2025. The next test is whether broader patient workflows generate lasting revenue.
Does medication access support a unicorn business?	Yes, investors have put a high price on treatment access. Forus raised a $150M Series C in September 2026. It coordinates tasks that begin after a doctor prescribes medicine.
Are documentation and coding valuable beyond transcription?	Yes, connecting notes to coding makes documentation commercially broader. Ambience Healthcare raised a $243M Series C to expand operations. Health system deployments show how that wider product can operate.
Can patient scheduling justify unicorn-level pricing now?	Apparently so, when automated access extends beyond answering calls. Assort Health is reportedly valued at $1.2B in private financing. Its agents connect scheduling, referrals, intake, and other related tasks.
Has billing automation produced a definite unicorn?	Not necessarily, because private funding prices can remain uncertain. Candid Health is estimated at $800M–$1.5B from its last round. Its lower bound does not establish a confirmed billion-dollar company.
Are European clinic agents already confirmed unicorns?	No, a promising upper estimate is not an announced price. Tandem Health is estimated at $667M–$1.2B from its last round. That range must be dated to September 2026 financing.
Can an early healthcare agent be worth a lot?	Yes, early platform ambitions can attract high private prices. Arbiter announced a $400M valuation at its Seed round. Execution and customer adoption must justify the price over time.
Are most private healthcare AI valuations directly observable?	No, many startups disclose fundraising without a complete price. Our review identifies 12 valuations stated by a source. The rest require careful estimates rather than invented certainty.
Do observed valuations align with money invested?	Not reliably, because investors price future growth, not past spending. Hippocratic AI's observed valuation-to-funding multiple stands at 8.7x. That measure says nothing directly about profit or revenue quality.